Skip to main content

Amylin: mode of action to clinical potential

Is amylin the missing piece of the puzzle when it comes to precision diabetology? Explore amylin’s diverse physiological functions and the evolution of amylin-based therapies, from key properties to clinical significance.

Read more

Editor's Choice

SGLT2 inhibitors linked to postop euglycemic ketoacidosis risk

Long-term SGLT2 inhibitor use is associated with an increased risk for postoperative euglycemic ketoacidosis but lower risks for postoperative acute kidney injury and mortality.

Diabetic foot in the context of rheumatic diseases

Understand the pathogenic mechanisms underlying diabetic foot development in patients with rheumatic diseases, the impact of chronic inflammation and drug therapy, and current diagnostic approaches, treatment strategies, and preventive measures.

Unexpected cause of pseudoascites in an adult with type 1 diabetes

A 64-year-old man with type 1 diabetes presented with notable abdominal swelling over the previous 3 months. Investigations led to a diagnosis of pseudoascites and celiac disease was identified as the cause.

Semaglutide reduces liver fibrosis and steatohepatitis in MASH

The diabetes and obesity treatment semaglutide, a GLP-1 receptor agonist, reduces liver fibrosis and steatohepatitis in adults with MASH, suggests an interim analysis of the ESSENCE trial.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Using CGM to optimize type 2 diabetes management with non-intensive insulin treatment in primary care

With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report. 

Supported by:
  • Abbott Diabetes Care
Prof. Samuel Seidu
Developed by: Adis
Listen now
Podcast

Case Studies

Unexpected cause of pseudoascites in an adult with type 1 diabetes

A 64-year-old man with type 1 diabetes presented with notable abdominal swelling over the previous 3 months. Investigations led to a diagnosis of pseudoascites and celiac disease was identified as the cause.

Skin infection or lymphoma in a woman with type 2 diabetes?

Cutaneous lymphoma should be considered in patients with long-standing, poorly controlled type 2 diabetes and chronic non-healing skin lesions. In this case, primary cutaneous B-cell lymphoma was misdiagnosed as a skin infection.

Colonic ischemia associated with a GLP-1 RA

Although it seems to be a rare complication, there should be a high index of suspicion for colonic ischemia in patients taking a GLP-1 receptor agonist who present with abdominal pain.

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more

Current Reviews

Evolving incretin-based therapies in Japan: optimizing treatment strategies for diverse clinical and socioeconomical profiles in type 2 diabetes

The management of type 2 diabetes has evolved significantly with the advent of incretin-based therapies, particularly dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists. In Japan, where over 70% of individuals with …

The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care

The global surge in obesity and type 2 diabetes mellitus (T2DM) presents significant challenges in orthopedic care, directly impacting musculoskeletal health and surgical outcomes. These metabolic disorders are associated with increased rates of …

Bone microstructure and TBS in diabetes: what have we learned? A narrative review

In 2021, one in ten adults , i.e., 537 million people were living with diabetes mellitus worldwide. It is predicted that this number will increase to 783 million by 2045. Diabetes mellitus brings many complications, of which bone fragility is the …

From receptor to response: dissecting the TLR4 pathway in diabetic neuropathy

Diabetic neuropathy (DNP) is a common complication of diabetes that has a significant impact on the patient’s quality of life. The primary objectives of clinical treatment for DNP these days are symptomatic pain management and glycemic control.

Episode 10: Disease-modifying therapy for type 1 diabetes

Reducing the burden of type 1 diabetes

Despite many recent advances in its management, type 1 diabetes remains a burden for those living with the condition.

Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.

Prof. Chantal Mathieu
Listen now
Podcast

CME & eLearning

Videos | Case Scenarios | Infographics (Link opens in a new window)

1.0 AMA PRA Category 1 Credit(s)

Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills.

Supported by:
  • Abbott
Developed by: Springer Healthcare IME

Vodcasts | Case Scenarios (Link opens in a new window)

Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.

This program is not available to users in the UK and US.

Supported by:
  • Novo Nordisk A/S
Developed by: Springer Healthcare IME

News | Expert Reviews | Cases (Link opens in a new window)

Treating children with hormone disorders is complex and requires tailored management. To help you provide the most effective care, we deliver resources covering adrenal, thyroid, pituitary, growth, and puberty disorders, obesity, and diabetes.

Supported by:
  • Merck Healthcare KGaA, Darmstadt, Germany
Developed by: Springer Healthcare IME

Further Reading

Peripheral Neuropathy Symptoms and Ocular Surface Lesions in Patients with Type 2 Diabetes Mellitus and Dry Eye: A Clinical Correlational Study

Diabetes represents one of the most rapidly escalating health challenges of the twenty-first century, with the global prevalence of diabetes among adults increasing more than threefold over the past two decades [ 1 ]. In 2021, approximately 10.5% …

Proinflammatory cytokine-induced alpha cell impairment in human islet microtissues is partially restored by dual incretin receptor agonism

The alpha cells of the pancreatic islets of Langerhans play a pivotal role in glucose homeostasis by secreting counterregulatory glucagon in response to low glucose levels, and this stimulates hepatic glucose output to prevent hypoglycaemia [ 1 ].

Evolving incretin-based therapies in Japan: optimizing treatment strategies for diverse clinical and socioeconomical profiles in type 2 diabetes

The management of type 2 diabetes has evolved significantly with the advent of incretin-based therapies, particularly dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists. In Japan, where over 70% of individuals with …

The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care

The global surge in obesity and type 2 diabetes mellitus (T2DM) presents significant challenges in orthopedic care, directly impacting musculoskeletal health and surgical outcomes. These metabolic disorders are associated with increased rates of …

Related topics

Amylin: mode of action to clinical potential

Is amylin the missing piece of the puzzle when it comes to precision diabetology? Explore amylin’s diverse physiological functions and the evolution of amylin-based therapies, from key properties to clinical significance.

Read more

Amylin: mode of action to clinical potential

Is amylin the missing piece of the puzzle when it comes to precision diabetology? Explore amylin’s diverse physiological functions and the evolution of amylin-based therapies, from key properties to clinical significance.

Read more

Diabetic foot in the context of rheumatic diseases

Understand the pathogenic mechanisms underlying diabetic foot development in patients with rheumatic diseases, the impact of chronic inflammation and drug therapy, and current diagnostic approaches, treatment strategies, and preventive measures.

Read more

Focus on insulin icodec

A thorough overview of the safety and efficacy of once-weekly basal insulin icodec in type 1 and 2 diabetes, covering pharmacology, pharmacokinetics, adverse effects, drug interactions, and dose recommendations.

Read more